Moderna Inc (NASDAQ:MRNA) posted a loss for the third quarter on Thursday.
Moderna reported a quarterly loss of $(9.53), down from EPS income of $2.53. The analysts’ estimate stood at $(1.93). The company’s sales reached $1.8 billion (all from COVID-19 vaccine), beating the consensus of $1.4 billion and down from $3.4 billion a year ago.
Moderna shares gained 9.1% to trade at $77.70 on Friday.
These analysts made changes to their price targets on Moderna following earnings announcement.
HSBC lowered the price target on Moderna from $89 to $69. HSBC analyst Yifeng Liu upgraded the stock from Reduce to Hold.
Goldman Sachs cut the price target on Moderna from $269 to $231. Goldman Sachs analyst Salveen Richter maintained a Buy rating.
Now Read This: Top 4 Financial Stocks That May Collapse This Quarter
